Encontrados 2 documentos, a visualizar página 1 de 1
Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or am...
HIRSCH‐REINSHAGEN, V.; CHAN, J.Y.; WILKINSON, A.; TANAKA, T.; FAN, J.; OU, G.; MAIA, L.F.; SINGARAJA, R.R.; HAYDEN, M.R.; WELLINGTON, C.L.J Lipid Res. 2007 Apr;48(4):914-23. Epub 2007 Jan 18. Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid-beta peptide levels in vivo. Hirsch-Reinshagen V, Chan JY, Wilkinson A, Tanaka T, Fan J, Ou G, Maia LF, Singaraja RR, Hayden MR, Wellington CL. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. Abstract ABCA1-deficient mic...
The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloi...
HIRSCH‐REINSHAGEN, V.; MAIA, L.F.; BURGESS, B.L.; BLAIN, J.F.; NAUS, K.E.; MCISAAC, S.A.; PARKINSON, P.F.; CHAN, J.Y.; TANSLEY, G.H.; HAYDEN, M.R.J Biol Chem. 2005 Dec 30;280(52):43243-56. Epub 2005 Oct 5. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, Poirier J, Van Nostrand W, Wellington CL. Department of Pathology and Laboratory Medicine, Univers...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||